COVID-19 : Pulmonary Ultrasound in Primary Care

NCT ID: NCT05226403

Last Updated: 2022-02-07

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 38 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-07-01
• Study Completion Date: 2021-12-31

Brief Summary

COVID-19 infection are characterized by fever and signs of acute respiratory infection. A worsening of respiratory symptoms that can lead to respiratory failure. The decompensation can then be brutal and require rapid recourse to respiratory assistance. The contribution of clinical examination (auscultation and monitoring of oxygen saturation in particular) remains unsatisfactory in predicting an unfavorable course. The interest of pulmonary ultrasound is known in the management of pulmonary infections. However, estimating the severity of lung damage at an early stage could be of great help in monitoring and caring for patients. Ultrasound could meet this need in general practice, the chest scanner is often unavailable in these situations.

Ultrasound signs are associated with severe forms. The contribution of pulmonary ultrasound seems particularly interesting in the context of the reassessment of patients during the worsening phase of symptoms (D5-D10).

Estimate the prevalence of ultrasound signs in patients with an acute respiratory infection suspected or confirmed to be COVID-19, at the time of the worsening phase (between D5 and D10 of the onset of symptoms).

The prevalence of ultrasound lung lesions under COVID-19 may be essential to consider the development of the ultrasound tool in primary care. Indeed, if the contribution of ultrasound is now recognized in intensive care or emergency, its place in general medicine still raises questions.

Conditions

Covid19; Pulmonary Infection; Ultrasound Therapy; Complications; Respiratory Infection

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

1. Patients over 18 years of age with :

• a clinical symptomatology suggesting an acute respiratory infection linked to COVID-19 defined by the following two categories of symptoms:

• Sudden fever (or a feeling of fever)
• Respiratory signs (cough, dyspnea, chest tightness) Or
• an acute respiratory infection confirmed to COVID-19 by the result of RT-PCR screening tests.

2. And presenting, at the time of inclusion between the 5th and 10th day of infection, one of the respiratory signs of severity felt:

• Dyspnea, shortness of breath or difficulty in breathing
• Chest pain or tightness

Exclusion Criteria

1. The presence of a severe form during the initial consultation. A severe form is defined by the presence of the following signs:

• Polypnea> 22 / min
• systolic BP <90 mmHg
• Sp02 <90%
• Altered consciousness, confusion, drowsiness
• Dehydration
• Alteration of the general condition in the elderly

2. The presence of acute respiratory signs clearly having a cause other than a COVID-19 infection.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Geprovas

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

GEPROVAS

Strasbourg, , France

Countries

France

Other Identifiers

2020-A01225-34

Identifier Type: -

Identifier Source: org_study_id